ASRT - デポメッド （Assertio Therapeutics Inc.） デポメッド

Assertio acquired a future blockbuster which may likely generate sales by itself are more than half the current market cap. Read why ASRT stock is a strong buy.

The world’s foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of prediction before. Back in December, Wall Street was bullish on Johnson & Johnson (NYSE: JNJ ). Analysts were convinced JNJ could only go up… but An-E knew better. The algorithm said that JNJ stock was headed down 10% over one month… and JNJ stock fell that exact amount. Wall Street was shocked… but An-E saw it coming long before everyone else. We’ve seen spot-on predictions for Vontier (NYSE: VNT )… Martin Marietta Materials (NYSE: MLM )… Domino’s Pizza (NYSE: DPZ ). Now this technology has flagged a big move coming in Assertio over the next 21 days. Investors who pay close attention can maximize their profits… and protect their retirement savings like never before. That’s because An-E combines artificial intelligence and machine learning. And AI is at an inflection point right now. The team at TradeSmith has spent $18 million and 50,000 hours developing software for retail investors, but An-E is unlike anything we’ve ever built.

Assertio Holdings Inc. (ASRT)’s stock is trading at $5.90 at the moment marking a rise of 2.61% from the last session close. As of this writing, shares are priced at -15.71% less than their 52-week high of $7.00, and 217.20% over their 52-week low of $1.86. Based on the past 30-day period, the stock price […]

Assertio Holdings stock fell 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95%. See why we believe ASRT stock is a buy.

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Management appears to have done a solid job putting Assertio''s troubled past behind. Click here to read my analysis of ASRT stock.

Assertio Holdings Inc. (NASDAQ:ASRT) price on Friday, November 11, rose 5.71% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.96. A look at the stock’s price movement, the close in the last trading session was $2.80, moving within a range at $2.81 and $2.97. The beta value … Is Assertio Holdings Inc. (NASDAQ: ASRT) A Top Momentum Pick? Read More »

Assertio Holdings Inc. (ASRT)’s stock has witnessed a price hike of 4.49% from the previous close with its current price standing at $2.79. Its current price is -37.16% under its 52-week high of $4.44 and 134.43% more than its 52-week low of $1.19. Based on the past 30-day period, the stock price is -0.36% below […]

Assertio Holdings Inc. (NASDAQ:ASRT) price is hovering higher on Wednesday, November 09, jumping 3.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $2.62, with intraday deals fluctuating between $2.58 and $2.70. The company’s 5Y monthly beta was ticking 1.49 while its P/E ratio in … Assertio Holdings Inc. (NASDAQ: ASRT) Shares Rose Recently, But Trouble Could Still Be Around The Corner. Read More »

https://www.investing.com/news/pro/assertio-therapeutics-pt-receives-investment-bank-analyst-rating-update-432SI-2937237

Assertio Holdings Inc. (NASDAQ:ASRT)’s traded shares stood at 1.47 million during the last session, with the company’s beta value hitting 1.49. At the close of trading, the stock’s price was $3.18, to imply a decrease of -2.75% or -$0.09 in intraday trading. The ASRT share’s 52-week high remains $3.52, putting it -10.69% down since that … Should You Expect Assertio Holdings Inc. (NASDAQ:ASRT) To Recover From Its 73.27% Gain From Highs? Read More »

Assertio, formerly DepoMed, nearly went under after a disastrous acquisition of opioid drug Nucynta. Has the tide turned for the biotech? Read why investors should steer clear of Assertio.

Finding stocks with a moonshot potential is like finding gold — you must know where to search, what criteria to use in a stock screener and how to make a narrow list of selections from that info. Even the best penny stocks to buy now are riskier than large-cap or mid-cap stocks. But while this is true, it is often a bad idea to neglect good penny stocks (and their potential for big gains). If you’re looking to expand into penny stocks, I have a few top picks to share with you. But first, what does moonshot potential mean? I would say that a return relatively higher than the average U.S. stock market return during the past 10 years meets the definition of a moonshot potential. I am not referring to a 100% increase but to be less realistic to return that is higher than the 28.7% gains of the S&P 500 in 2021 . For example, 40% or 50% would be a great return. 7 Top-Rated Large-Cap Stocks to Buy and Hold Can the best penny stocks to buy now move even higher? I would say yes, but don’t throw everything at them.

Several analysts have recently updated their ratings and price targets for Assertio : 6/6/2022 - Assertio was downgraded by analysts at StockNews.com from a “strong-buy” rating…

LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced its participation in the LD Micro Invitational XII Conference on June 7-9, 2022. The conference is being held at the Four Seasons Hotel Westlake Village near Los Angeles, CA. This will be an in-person conference with Assertio presenting on Wednesday, June 8, 2022, at 3:00 pm pacific time in Track 1 and hosting 1:1 meetings with investors throughout the day.